Chemistry Reference
In-Depth Information
137. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M,
Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg
G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. Mevinolin: a highly
potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a
cholesterol-lowering agent. Proc. Natl. Acad. Sci. U.S.A. 1980;77:3957-3961.
138. Patchett AA. 2002 Alfred Burger Award Address in Medicinal Chemistry. Natu-
ral products and design: interrelated approaches in drug discovery. J. Med. Chem.
2002;45:5609-5616.
139. Coukell AJ, Wilde MI. Pravastatin. A pharmacoeconomic review of its use in
primary and secondary prevention of coronary heart disease. Pharmacoeconomics
1998;14:217-236.
140. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the
management of hypercholesterolaemia. Drugs 1996;51:433-459.
141. Roth BD. The discovery and development of atorvastatin, a potent novel hypolipi-
demic agent. Prog. Med. Chem. 2002;40:1-22.
142. Plosker GL, Dunn CI, Figgitt DP. Cerivastatin: a review of its pharmacological
properties and therapeutic efficacy in the management of hypercholesterolaemia.
Drugs 2000;60:1179-1206.
143. Chong PH, Yim BT. Rosuvastatin for the treatment of patients with hypercholes-
terolemia. Ann. Pharmacother. 2002;36:93-101.
144. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-
converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elu-
cidation of structure, and synthesis. Biochemistry 1971;10:4033-4039.
145. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-
converting enzyme: new class of orally active antihypertensive agents. Science
1977;196:441-444.
146. Burg RW, Miller BM, Baker EE, Birnbaum J, Currie SA, Hartman R, Kong YL,
Monaghan RL, Olson G, Putter I, Tunac JB, Wallick H, Stapley EO, Oiwa R, Omura
S. Avermectins, new family of potent anthelmintic agents: producing organism and
fermentation. Antimicrob, Agents Chemother. 1979;15:361-367.
147. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LH, Schaeffer JM,
Arena JP. Cloning of an avermectin-sensitive glutamate-gated chloride channel from
Caenorhabditis elegans. Nature 1994;371:707-711.
148. Davies HG, Green RH. Avermectins and milbemycins. Nat. Prod. Rep. 1986;3:
87-121.
149. Chabala JC, Mrozik H, Tolman RL, Eskola P, Lusi A, Peterson LH, Woods MF,
Fisher MH, Campbell WC, Egerton JR, Ostlind DA. Ivermectin, a new broad-
spectrum antiparasitic agent. J. Med. Chem. 1980;23:1134-1136.
150. Goa KL, McTavish D, Clissold SP. Ivermectin. A review of its antifilarial activity,
pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs 1991;42:
640-658.
151. Kirst HA, Creemer LC, Naylor SA, Pugh PT, Snyder DE, Winkle JR, Lowe LB,
Rothwell JT, Sparks TC, Worden TV. Evaluation and development of spinosyns to
control ectoparasites on cattle and sheep. Curr. Top. Med. Chem. 2002;2:675-699.
152. Ondeyka JG, Helms GL, Hensens OD, Goetz MA, Zink DL, Tsipouras A, Shoop
WL, Slayton L, Dombrowski AW, Polishook JD, Ostlind DA, Tsou NN, Ball RG,
